<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965961</url>
  </required_header>
  <id_info>
    <org_study_id>H-18013069</org_study_id>
    <nct_id>NCT04965961</nct_id>
  </id_info>
  <brief_title>The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females</brief_title>
  <official_title>Plasma and Exosome Proteomic Changes Associated With Augmented Erythropoiesis and Muscle Contractions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant human erythropoietin (rHuEPO) regimen enhances maximal oxygen consumption&#xD;
      (VO2max), but the effect of micro-doses on maximal and submaximal performance is not clear&#xD;
      and detection of micro-doses is difficult with current methods. This study investigated&#xD;
      whether micro-doses of rHuEPO enhances maximal and endurance performance in males and&#xD;
      females.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized, double-blind, placebo-controlled design, 48 trained adults (24 females, 24&#xD;
      males) receive either recombinant human erythropoietin (rHuEPO; epoetin-β, 9 IU/kg, n = 24,&#xD;
      (12 females, 12 males)) or placebo (0,9% NaCl, n = 24, (12 females, 12 males)) three times&#xD;
      per week for four weeks. Before the intervention, time trial performance and maximal oxygen&#xD;
      uptake will be assessed. Three and five days after the last injection, time trial performance&#xD;
      and maximal oxygen uptake will be determined to assess the effect of the rHuEPO&#xD;
      administration. In addition, total hemoglobin mass and intravascular volumes will be&#xD;
      determined via the carbon monoxide rebreathing method in duplicate measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Explorative</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>An algorithm was created using randomizer.org</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maximal oxygen uptake</measure>
    <time_frame>Change from baseline to 5 days after last injection</time_frame>
    <description>Change from baseline maximal aerobic capacity 5 days after last injection. Measured via an exhaustive incremental cycle ergometer test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in time trial performance</measure>
    <time_frame>Change from baseline to 3 days after last injection</time_frame>
    <description>Change from baseline endurance exercise performance 3 days after last injection. Measured via a preloaded 400 kcal time-trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total hemoglobin mass</measure>
    <time_frame>Change from baseline to 3 days after last injection</time_frame>
    <description>Change from baseline total hemoglobin mass 3 days after last injection. Measured by the carbon monoxide rebreathing method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Sports Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Recombinant human erythropoietin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive intravenous injections of 9 International Units per kg bodyweight epoetin-β (NeoRecormon, Roche, Mannheim, Germany) three times per week for four weeks on non-consecutive days. Subjects receive tablets with 80mg iron (Tardyferon, Pierre Fabre Pharme GmbH, Freiburg, Germany) to ensure sufficient iron stores for the expected increase in erythropoeisis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive intravenous injections of ~0,5 mL saline (NaCl 0,9%) three times per week for four weeks on non-consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO</intervention_name>
    <description>Please refer to the arm description</description>
    <arm_group_label>Recombinant human erythropoietin treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group - saline injection</intervention_name>
    <description>Please refer to the arm description</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relative maximum oxygen uptake (VO2-max) of at least 50 ml O2/min/kg for male&#xD;
             participants and 45 ml O2/min/kg for female participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&#xD;
&#xD;
          -  Insufficient fitness level&#xD;
&#xD;
          -  Blood donation 3 months prior to enrollment&#xD;
&#xD;
          -  Altitude exposure 2 months before enrollment&#xD;
&#xD;
          -  Hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Nutrition, Exercise and Sports</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Nikolai Nordsborg</investigator_full_name>
    <investigator_title>Professor, Head of Department</investigator_title>
  </responsible_party>
  <keyword>erythropoeitin</keyword>
  <keyword>doping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Fully anonymous data can be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

